Elevated Aβ aggregates in feces from Alzheimer's disease patients: a proof-of-concept study

被引：1

作者：

Pils, Marlene ^{[1
,2
]}

Dybala, Alexandra ^{[3
]}

Schaffrath, Anja ^{[1
]}

Rehn, Fabian ^{[1
,2
]}

Kutzsche, Janine ^{[1
]}

Bloemeke, Lara ^{[1
]}

Tusche, Markus ^{[1
]}

Oezduezenciler, Pelin ^{[1
]}

Bujnicki, Tuyen ^{[1
]}

Kraemer-Schulien, Victoria ^{[1
]}

Gramespacher, Hannes ^{[4
]}

Schmieschek, Maximilian H. T. ^{[4
]}

Barbe, Michael T. ^{[4
]}

Onur, Oezguer A. ^{[4
,5
]}

Fink, Gereon R. ^{[4
,5
]}

Tamguney, Gultekin ^{[1
,3
]}

Bannach, Oliver ^{[1
,2
]}

Willbold, Dieter ^{[1
,2
,3
]}

机构：

[1] Forschungszentrum Julich, Inst Biol Informat Proc, Struct Biochem IBI 7, D-52428 Julich, Germany

[2] attyloid GmbH, D-40225 Dusseldorf, Germany

[3] Heinrich Heine Univ Dusseldorf, Inst Phys Biol, D-40225 Dusseldorf, Germany

[4] Univ Cologne, Univ Hosp Cologne, Fac Med, Dept Neurol, D-50937 Cologne, Germany

[5] Res Ctr Julich, Inst Neurosci & Med INM 3, Cognit Neurosci, D-52428 Julich, Germany

来源：

ALZHEIMERS RESEARCH & THERAPY | 2024年 / 16卷 / 01期

关键词：

Amyloidosis; A beta oligomer quantitation; sFIDA; Brain-gut-microbiota axis; Leaky gut; Fecal/stool samples; Clearance; MILD COGNITIVE IMPAIRMENT; CEREBROSPINAL-FLUID; GUT-MICROBIOTA; DIAGNOSIS; BRAIN;

D O I：

10.1186/s13195-024-01597-3

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

BackgroundMisfolding and aggregation of amyloid beta (A beta), along with neurofibrillary tangles consisting of aggregated Tau species, are pathological hallmarks of Alzheimer's disease (AD) onset and progression. In this study, we hypothesized the clearance of A beta aggregates from the brain and body into the gut.MethodsTo investigate this, we used surface-based fluorescence intensity distribution analysis (sFIDA) to determine the A beta aggregate concentrations in feces from 26 AD patients and 31 healthy controls (HC).ResultsA beta aggregates were detectable in human feces and their concentrations were elevated in AD patients compared to HC (specificity 90.3%, sensitivity 53.8%).ConclusionThus, fecal A beta aggregates constitute a non-invasive biomarker candidate for diagnosing AD. Whether digestion-resistant A beta aggregates in feces are secreted via the liver and bile or directly from the enteric neuronal system remains to be elucidated.

引用

页数：15

共 50 条

[41] Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study
Eric McDade
Jeffrey L. Cummings
Shobha Dhadda
Chad J. Swanson
Larisa Reyderman
Michio Kanekiyo
Akihiko Koyama
Michael Irizarry
Lynn D. Kramer
Randall J. Bateman
Alzheimer's Research & Therapy, 14
[42] Improvements in clinical signs of Parkinson's disease using photobiomodulation: a prospective proof-of-concept study
Liebert, Ann
Bicknell, Brian
Laakso, E-Liisa
Heller, Gillian
Jalilitabaei, Parastoo
Tilley, Sharon
Mitrofanis, John
Kiat, Hosen
BMC NEUROLOGY, 2021, 21 (01)
[43] Improvements in clinical signs of Parkinson’s disease using photobiomodulation: a prospective proof-of-concept study
Ann Liebert
Brian Bicknell
E-Liisa Laakso
Gillian Heller
Parastoo Jalilitabaei
Sharon Tilley
John Mitrofanis
Hosen Kiat
BMC Neurology, 21
[44] Wearable haptic anklets for gait and freezing improvement in Parkinson’s disease: a proof-of-concept study
Simone Rossi
Tommaso Lisini Baldi
Marco Aggravi
Monica Ulivelli
David Cioncoloni
Viola Niccolini
Lorenzo Donati
Domenico Prattichizzo
Neurological Sciences, 2020, 41 : 3643 - 3651
[45] Wearable haptic anklets for gait and freezing improvement in Parkinson's disease: a proof-of-concept study
Rossi, Simone
Baldi, Tommaso Lisini
Aggravi, Marco
Ulivelli, Monica
Cioncoloni, David
Niccolini, Viola
Donati, Lorenzo
Prattichizzo, Domenico
NEUROLOGICAL SCIENCES, 2020, 41 (12) : 3643 - 3651
[46] Prediagnostic expressions in health records predict mortality in Parkinson's disease: A proof-of-concept study
Kuusimaki, Tomi
Sainio, Jani
Kurki, Samu
Vahlberg, Tero
Kaasinen, Valtteri
PARKINSONISM & RELATED DISORDERS, 2022, 95 : 35 - 39
[47] Bioremediation of hydrocarbons from contaminated wood: A proof-of-concept study
Popova, IE
Beklemishev, MK
Kozliak, EI
ENGINEERING IN LIFE SCIENCES, 2005, 5 (03): : 223 - 233
[48] Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer's disease
Cummings, Jeffrey L.
Zhong, Kate
Kinney, Jefferson W.
Heaney, Chelcie
Moll-Tudla, Joanne
Joshi, Abhinay
Pontecorvo, Michael
Devous, Michael
Tang, Anne
Bena, James
ALZHEIMERS RESEARCH & THERAPY, 2016, 8
[49] SUVN-502, A novel, potent and pure 5-HT6 receptor antagonist - proof-of-concept study design in moderate Alzheimer's disease patients
Nirogi, Venkata Satya Ramakrishna
Sastry, Kambhampati
Shinde, Anil
Rasheed, Mohammed
Badange, Rajesh
Bandyala, Thrinath
Bhatta, Venugopalarao
Reballi, Veena
Achanta, Pramod Kumar
Kandukuri, Kiran Kumar
Bojja, Kumar
Saraf, Sangram Keshari
Mudigonda, Koteshwara
Jayarajan, Pradeep
Bhyrapuneni, Gopinadh
Goyal, Vinod Kumar
Jasti, Venkat
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 254
[50] HARBOR: ABBV-916 In Subjects With Early Alzheimer's Disease Combined Multiple-Ascending Dose/Proof-Of-Concept Study Design
Watson, David
Lynch, Shau Yu
Florian, Hana
Wang, Deli
Bachhav, Sagar
Boiser, Joey
Bannon, Anthony
Stage, Edwin
Graff, Ole
NEUROLOGY, 2023, 100 (17)

← 1 2 3 4 5 →